Long COVID clinical trials/studies involving CBMPs (also including CBD/hemp-based supplements)
| NCT number | Title | Country | Status | Study design | Participants | Condition | Intervention | Publications |
|---|---|---|---|---|---|---|---|---|
| NCT04997395 | Feasibility of cannabidiol for the treatment of Long COVID | UK | Active, not recruiting | Phase 2, open label | Adults over 18. N = 30 | Long COVID | MediCabilis 5% CBD Oil (UK trade name: MediCabilis™ Cannabis sativa 50). Daily dose up to 150 mg CBD, 6 mg THC for 5 months | Not published |
| NCT05467904 | Double-blind randomized placebo-controlled trial of a proprietary full hemp flower formulation for Long COVID | USA | Not yet recruiting | Placebo controlled. Phase not stated | Adults 18–65. N = 111 | Post-acute COVID-19 syndrome (Long COVID) | Full hemp flower formulation (Xltran Plus™ and Xltran™) for 28 days | Not published |
| NCT04828668 | Study to evaluate benefits & safety of Endourage Formula C™ oral drops in people with post-acute COVID-19 syndrome | USA | Completed | Placebo controlled. Phase not stated | Adults 18–75. N = 60 | Post-acute COVID-19 syndrome (Long COVID) | Formula C™ sublingual drops for 28 days (Extracted from hemp flower) | Published [114] |
USA: United States of America; N: refers to the number of study participants
HT, AKS, and EI: Conceptualization, Writing—original draft, Writing—review & editing. AH and ML: Conceptualization, Writing—review & editing. DJN: Conceptualization, Writing—review & editing, Supervision. All authors read and approved the submitted version.
Author DJN is the Chair of the charity Drug Science. Author ML is the Chief Research Officer of Drug Science. Author AKS is the Head of Research of Drug Science and scientific advisor to the Primary Care Cannabis Network, and an executive member of the Cannabis Industry Council, both unpaid roles. Author HT is a Senior Research Officer and Study Coordinator of the medical cannabis and Long COVID clinical trial at Drug Science. Author EI is an expert member of the Drug Science Medical Cannabis Working and Principial Investigator of medical cannabis and Long COVID clinical trial at Drug Science. Drug Science receives an unrestricted educational grant from a consortium of medical cannabis companies to further its mission, which is the pursuit of an unbiased and scientific assessment of drugs regardless of their regulatory class. All Drug Science committee members, including the Chair, are unpaid by Drug Science for their effort and commitment to this organization. None of the authors would benefit from the wider prescription of medical cannabis in any form. AH was Chief Scientific Officer at Bod Australia Limited which is the sponsor of a medical cannabis and Long COVID clinical trial at Drug Science.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2023.